Clinical Trial

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Study acronym: Belvedere
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2028-03-31 -> 2027-09-30 2026-05-13
minor Completion moved earlier: 2028-04-30 -> 2027-10-29 2026-05-13
Trial Details
NCT Number NCT04853251
Lead Sponsor Genentech, Inc.
Conditions Neovascular Age-related Macular Degeneration
Enrollment 188 participants
Start Date 2021-12-14
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-10-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-10